腺相关病毒载体介导的Endostatin及K1-5蛋白抗肿瘤血管生成协同作用

为研究腺相关病毒载体介导的内皮抑素(Endostatin)及K1-5蛋白抗肿瘤血管生成协同作用,实验中用含有Endostatin及K1-5基因的重组病毒rAAV-hE和rAAV-K5分别感染BHK-21细胞,并表达分泌出内皮抑素和K1-5蛋白,EIA法测定培养液上清中内皮抑素浓度达36.42ng/m l,免疫斑点印迹实验表明rAAV-K5可介导K1-5的体外表达。重组腺相关病毒(rAAV)介导所表达的内皮抑素和K1-5蛋白对血管内皮细胞增殖具有抑制作用。二者对人脐静脉内皮细胞(ECV-304)的抑制率分别为68.1%和63.1%,对牛毛细血管内皮细胞(BCE)的抑制率分别为41.6%和34.0%。同时二者还有协同效应,用rAAV-hE和rAAV-K5同时感染BHK-21细胞,表达产物对人脐静脉内皮细胞和牛毛细血管内皮细胞的抑制率分别为70.8%和43.8%。动物实验表明,重组病毒rAAV-hE和rAAV-K5转入荷有人肺肿瘤细胞的裸鼠,对肿瘤细胞生长具有抑制作用,同时二者具有协同抗肿瘤作用。     

血管生成素样蛋白3与疾病

血管生成素样蛋白3（angiopoietin-like protein3,ANGPTL3）是一种分泌蛋白,因其具有血管生成素家族的特征性结构而得名。该蛋白质主要在人和鼠的肝脏表达,可能与脂代谢紊乱、冠心病与动脉粥样硬化、糖尿病、代谢综合征、肾病以及肝癌等疾病有关。因此深入研究该蛋白质与疾病的关系,可望为诊断、治疗、预防相关疾病提供新的途径。     

Kringle5蛋白生物学作用及机制

Kringle5是血浆纤维蛋白溶酶原的第五个饼环区结构域,在体外具有抑制内皮细胞增殖和迁移、在体内具有抑制血管新生和肿瘤生长的生物活性,在实体瘤、糖尿病视网膜病变、风湿性关节炎等疾病的治疗中有广泛的应用前景。     

重组人纤溶酶原K1-3蛋白的抗肿瘤活性研究

人纤溶酶原K1-3功能区是一个血管生成抑制因子。以人纤溶酶原k1-3基因在大肠杆菌中表达的重组K1-3蛋白进行鸡胚绒毛尿囊膜(chorioallantoicmembrane,CAM)血管生成抑制活性分析和小鼠B16黑色素瘤抑瘤实验,结果证实重组K1-3蛋白具有抑制毛细血管生成和抗肿瘤活性。     

重组人纤溶酶原Kringle1-5的制备及其

为了研究重组人纤溶酶原 Kringle1-5(K1-5)的抗血管生成活性及其对内皮细胞增殖的影响, 通过PCR扩增人纤溶酶原K1-5 cDNA,定向克隆于原核表达载体pET30a(+)中,构建重组表达载体pET-K1-5, 转化E.coli BL21(DE3), IPTG诱导表达,SDS-PAGE 和Western 杂交检测K1-5的表达。鸡胚尿囊膜 (CAM) 实验和MTT实验分别检测重组人纤溶酶原Kringle1-5对鸡胚新生血管生成和内皮细胞的抑制作用。结果表明,IPTG诱导原核表达载体pET-K1-5在E.coli BL21(DE3)中的表达量约占菌体总蛋白量的32%, K1-5主要以包涵体形式存在,包涵体经过洗涤、溶解、Ni-spin 亲合柱层析纯化以及蛋白质复性等步骤后,获得了纯度约为96%的重组K1-5蛋白。CAM实验表明,原核表达的重组人K1-5能有效地按剂量依赖的方式抑制鸡胚新生血管的形成。MTT实验结果显示,重组人K1-5特异地抑制内皮细胞的增殖, 而对非内皮细胞无抑制作用。     

窖蛋白-3及其与人类肌肉疾病的关系

窖蛋白-3(caveolin-3,Cav-3)是整合在窖上的肌细胞特异性蛋白质。人cav-3基因定位于3p25,其主要突变包括跨膜区的错义突变及支架区的染色体微缺失,所导致的表现型包括肢带型肌营养不良(1imb-girdle muscular dystrophy-1C,LGMD-1C)、杜氏肌营养不良(Duchenne muscular dystrophy,DMD)、自发性和家族性高CK血症(hyper CKemia,HCK)、末端肌病(distal myopathy,DM)和波形肌肉疾病(rippling muscle disease．RMD)等。Cav-3不仅与肌肉营养不良症相关,也是维持心脏正常功能的必要因素。     

缺眼蛋白的结构、功能与疾病

缺眼蛋白（eyes absent,Eya）是进化上高度保守的转录因子,首次在果蝇眼发育中被发现。后被证明,缺眼蛋白参与多种生物学过程,例如器官发育、先天免疫、DNA损伤修复、光周期、血管生成与肿瘤发生发展等。上述生物学功能与缺眼蛋白具有多种不同生化活性有关,包括转录激活活性、酪氨酸磷酸酶活性和苏氨酸磷酸酶活性。缺眼蛋白不同的生化活性存在于不同的结构域中。本文主要针对缺眼蛋白3个保守的结构域ED、PST、TPM以及它们在发育和疾病中的功能作简要综述。     

层粘连蛋白与疾病相关性的研究进展

层粘连蛋白(lanminin,LN)是由3条多肽链组成的异源三聚体,是基膜的主要成分,存在于多种组织中,它可识别细胞表面受体从而使基膜与细胞紧密结合。LN参与基膜的构建及细胞的黏附、生长、增殖、迁移和分化,是机体正常生长发育所必需的。LN的不正常表达常常与肿瘤以及皮肤、神经-骨骼肌、肝、肾等组织疾病的发生发展密切相关。通过深入探讨LN与疾病及肿瘤发生、发展的关系,有望为相关疾病及肿瘤的治疗开拓新的思路。     

G蛋白与血管反应性

Ｇ蛋白是细胞跨膜信息传递中的一个重要环节,近年发现,Ｇ蛋白系统与血管反应性关系密切,参与多种血管活性物质的产生和作用,Ｇ蛋白功能异常,尚可导致一些血管疾病的发生。     

缺眼蛋白的结构、功能与疾病北大核心CSCD

缺眼蛋白(eyes absent,Eya)是进化上高度保守的转录因子,首次在果蝇眼发育中被发现。后被证明,缺眼蛋白参与多种生物学过程,例如器官发育、先天免疫、DNA损伤修复、光周期、血管生成与肿瘤发生发展等。上述生物学功能与缺眼蛋白具有多种不同生化活性有关,包括转录激活活性、酪氨酸磷酸酶活性和苏氨酸磷酸酶活性。缺眼蛋白不同的生化活性存在于不同的结构域中。本文主要针对缺眼蛋白3个保守的结构域ED、PST、TPM以及它们在发育和疾病中的功能作简要综述。     

Fibulin-5在主动脉夹层血管壁中表达异常

目的:研究Stanford A型主动脉夹层(aortic dissection,AD)升主动脉和正常升主动脉血管组织中Fibulin-5表达的差异。方法:收集Stanford A型AD患者手术中切除的升主动脉血管组织标本12例(AD组),多器官捐献患者升主动脉血管12例(对照组)。采用EVG染色观察主动脉中膜弹性纤维形态结构;应用SP免疫组织化学法及Western blot法对标本组织中的Fibulin-5进行检测分析。结果:AD组主动脉中膜弹性纤维形态和排列不规则、破碎、丢失,结构紊乱。免疫组织化学显示Fibulin-5阳性表达见于主动脉壁平滑肌细胞胞质中,AD组与对照组比较,Fibulin-5表达明显较少。Western blot蛋白印迹示AD组Fibulin-5表达明显减少,差异有统计学意义(P0.05)。结论:Fibulin-5在AD主动脉中膜中表达下调,可能在AD的发生中发挥作用。     

Fibulin-5在三阴型乳腺癌细胞侵袭中的功能研究

的：研究Fibulin-5蛋白在三阴性乳腺癌（TNBC）m胞转移中的作用。方法：以三阴性乳腺癌细胞系（MDA-MB-231）分化而来的三株高中低不同转移能力的子细胞系为模型,高表达和抑制Fibulin．5在其中的表达,研究其对细胞侵袭能力的影响。结果：三阴性乳腺癌细胞内本底的Fibulin．5与其转移能力正相关,另外上调和抑制Fibulin-5可以改变其原有的侵袭能力。结论：Fibulin-5在三阴性乳腺癌细胞转移中发挥重要作用,抑制Fibulin-5可以降低三阴性乳腺癌细胞的侵袭能力。     

Effects of fibulin-5 on attachment, adhesion, and proliferation of primary human endothelial cells

BACKGROUND: Fibulin-5 is a novel extracellular protein that is thought to act as a bridging peptide between elastin fibers and cell surface integrins in blood vessel wall. Fibulin-5 binding to endothelial cell (EC) surface integrins may effect cell proliferation and cell attachment to extracellular matrix (ECM) or to artificial surfaces. In this paper, we describe the effects of fibulin-5 on attachment, adhesion, and proliferation of primary human EC. After demonstrating that fibulin-5 over-expression inhibited EC proliferation, we tested the hypothesis that co-expression of fibulin-5 and VEGF165 will lead to unique EC phenotype that will exhibit increased adherence properties and retain its proliferation capacity. METHODS AND RESULTS: Fibulin-5 and VEGF165 gene transfer to primary human saphenous vein endothelial cells was accomplished using retroviral vectors encoding the two genes. Transgene expression was verified using immunohistochemistry, Western blotting, and ELISA. Fibulin 5 over-expression tended to improve immediate EC attachment (30 min after seeding) and improved significantly adhesion (>40%) under shear stress tested 24h after EC seeding. The effects of fibulin-5 and VEGF165 on EC proliferation in the presence or absence of basic FGF were also tested. EC expressing fibulin-5 had reduced proliferation while VEGF165 co-expression ameliorated this effect. CONCLUSION: Fibulin-5 improved EC attachment to artificial surfaces. Dual transfer of fibulin-5 and VEGF165 resulted in EC phenotype with increased adhesion and improved proliferation. This unique EC phenotype can be useful for tissue engineering on endovascular prostheses.     

Biophysical Characterisation of Fibulin-5 Proteins Associated with Disease

FBLN5 encodes fibulin-5, an extracellular matrix calcium-binding glycoprotein that is essential for elastic fibre formation. FBLN5 mutations are associated with two distinct human diseases, age-related macular degeneration (AMD) and cutis laxa (CL), but the biochemical basis for the pathogenic effects of these mutations is poorly understood. Two missense mutations found in AMD patients (I169T and G267S) and two missense mutations found in CL patients (G202R and S227P) were analysed in a native-like context in recombinant fibulin-5 fragments. Limited proteolysis, NMR spectroscopy and chromophoric calcium chelation experiments showed that the G267S and S227P substitutions cause long-range structural effects consistent with protein misfolding. Cellular studies using fibroblast cells further demonstrated that these recombinant forms of mutant fibulin-5 were not present in the extracellular medium, consistent with retention. In contrast, no significant effects of I169T and G202R substitutions on protein fold and secretion were identified. These data establish protein misfolding as a causative basis for the effects of G267S and S227P substitutions in AMD and CL, respectively, and raise the possibility that the I169T and G202R substitutions may be polymorphisms or may increase susceptibility to disease.     

Vascular disrupting agents

It has been well established that a functioning vascular supply is essential for solid tumor growth and metastases. In the absence of a viable vascular network, tumors are unable to grow beyond a few millimeters and therefore remain dormant. Initiation of angiogenesis allows for continued tumor growth and progression. Targeting tumor vasculature, either by inhibiting growth of new tumor blood vessels (antiangiogenic agents) or by destroying the already present tumor vessels (vascular disrupting agents; VDA), is an area of extensive research in the development of new antitumor agents. These two groups differ in their direct physiological target, the type or extent of disease that is likely to be susceptible, and the treatment schedule. VDAs target the established tumor blood vessels, resulting in tumor ischemia and necrosis. These agents show more immediate effects compared to antiangiogenic agents and may have more efficacy against advanced bulky disease. VDAs can be divided into two groups--ligand-bound and small molecule agents. Both VDA groups have demonstrated antitumor effects and tumor core necrosis, but consistently leave a thin rim of viable tumor cells at the periphery of the tumor. More evidence suggests VDAs will have their greatest effect in combination with conventional chemotherapy or other modes of treatment that attack this outer rim of cells.     

内皮抑素在新生血管形成相关疾病中的作用机制研究进展

新血管形成是许多生理、病理过程的关键步骤,受血管形成促进因子和抑制因子的调节。内皮抑素是最重要的血管形成抑制因子之一,可在体外抑制血管内皮细胞的增殖、迁移和血管化,在动物模型中抑制新血管形成,对新生血管形成相关疾病,特别是肿瘤有治疗作用。关于内皮抑素抑制新血管形成的分子机制尚无定论,已有线索表明,它可通过与VEGF、MMP-2、整合素以及VEGF受体KDR等相互作用,从而抑制内皮细胞增殖、迁移或通过多种途径促进内皮细胞凋亡。本就内皮抑素作用的分子机制,及其作用于新血管形成相关疾病的最新研究成果进行综述。     

Molecular control of vascular development in the zebrafish

The zebrafish is emerging as a novel model for the study of embryonic vascular development. In this review we summarize the advantages of this intriguing experimental system and the advances in our understanding of the molecular control of vascular development it has allowed.     

血管内皮生长因子和抗肿瘤血管新生药物研究进展

肿瘤的生长与迁移离不开新血管的形成,这使得抗血管新生成为肿瘤治疗的重要途径之一。血管内皮生长因子（VEGF）是针对内皮细胞作用最强、特异性最高的血管新生促进因子,因而VEGF是抗肿瘤治疗的重要靶点。我们简要介绍了VEGF的一些生物学特点及肿瘤血管新生,着重介绍了一些抗血管新生药物的最新研究成果及其临床应用。     

促血管生成素的生物学特点和应用前景

促血管生成素（Ang）家族是调节血管生成的一类细胞因子,包括Ang-1、Ang-2、Ang-3和Ang-4等4个成员,Ang-1和Ang-2是其中最重要的成员。Tie-2是Ang家族的共同受体。Ang-1与Tie-2结合后激活下游信号通路,起到抑制内皮凋亡、促进内皮存活和迁移、维持血管完整性的作用;Ang-2则是Ang-1天然的抑制剂,其拮抗的效应与局部血管内皮生长因子（VEGF）的水平有关,VEGF存在时促进新生血管形成,VEGF缺乏时则有利于血管的消退。Ang参与生理和病理性的血管新生,与肿瘤和其他疾病有密切的关系,有广泛的应用前景。